Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

PMI vs MBI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MBI Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–4 Matrix Metrics)

MBI Overall Winner 6-Pillar Tally: PMI 1 – 5 MBI Matrix Metrics: PMI 4 – 5 MBI

As of Nov 19, 2026, MBIA Inc. (MBI) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas MBI carries 44.0/100 (HOLD) at $4.37 (87.0x Forward P/E, 22.8% operating margin).

  • Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. MBI 44.0/100 HOLD), MBI captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (22.8% vs. -248.1% operating margin) and revenue trajectory (+46.7% vs. +38.6% YoY).
  • Technical & Structure Timing Caution: PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1); meanwhile MBI is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 40.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PMI vs MBI
PMI NYSE American
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62
MBI NYSE Head-to-Head Winner
MBIA Inc.
Surety Insurance
$4.37
-2.24% 1D
Market Cap $228.1M
TTM Revenue $101M
Forward P/E 87.0x
Beta / 30D Vol 0.25β · 31% Vol
Unified Composite Score
44.0 / 100 HOLD
Tech 46.0 Fund 52.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -2.5%) with fading momentum, RSI 41
RSI-14: 40.8 · SMA20: $4.55 · SMA50: $4.49

6-Pillar Scorecard Institutional Category Breakdown (PMI 1 – 5 MBI)

Columns: Metric · PMI · MBI
1. Valuation Multiples MBI
Forward P/E N/M 87.0x
Trailing P/E 2.9x 87.0x
PEG Ratio N/M 1.71x
EV / Revenue 3.2x 2.3x
2. Growth & Scale MBI
Revenue Growth (YoY) +38.6% +46.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $6.3M $101M
Market Cap $17.1M $228.1M
3. Profitability & Quality MBI
Gross Margin 18.6% 88.1%
Operating Margin -248.1% 22.8%
Net Profit Margin 0.0% -159.4%
Return on Equity (ROE) 0.0% 0.0%
4. Balance Sheet & Cash Flow MBI
Cash Generation (TTM) -$17M -$120M
Cash Flow Margin N/A -118.8%
Net Cash / Leverage $3.2M Net Debt 0.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PMI
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 46.5% (10th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Distribution
6. R&D & Supply-Chain Moat MBI
OpEx & R&D Intensity N/A 65.3% of Rev ($66M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Insurance - Specialty Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PMI (4) vs MBI (5)
Institutional Metric PMI MBI Criterion Row Edge
Market Capitalization
Scale
$17.1M $228.1M Larger Scale MBI
Trailing P/E Ratio
Valuation
2.9x 87.0x Lower Multiple PMI
Forward P/E Ratio
Valuation
N/M 87.0x Lower Multiple MBI
Revenue Growth (YoY)
Growth
+38.6% +46.7% Higher Growth MBI
Operating Margin (TTM)
Profitability
-248.1% 22.8% Higher Margin MBI
Net Profit Margin
Profitability
0.0% -159.4% Higher Margin PMI
Return on Equity (ROE)
Capital Efficiency
0.0% 0.0% Higher ROE Tie
52-Week Range Position
Momentum
34% ($0–$18) 5% ($4–$8) Stronger Trend PMI
Beta / 30D Volatility
Risk Regime
54.06β · 134% Vol 0.25β · 31% Vol Lower Realized Risk MBI
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 44.0 / 100 (HOLD) Higher Composite PMI
Trailing 12M Revenue (USD)
Operating Scale
$6.3M $101M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.6% 88.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev 1.71x PEG · 2.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($3.2M Net Debt) -$120M (0.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MBI +33.67 pp
PMI: -34.58% · MBI: -0.91%
3M Horizon PMI +107.08 pp
PMI: +96.26% · MBI: -10.82%
6M Horizon PMI +3468.62 pp
PMI: +3439.33% · MBI: -29.29%
1Y Horizon PMI +190.83 pp
PMI: +148.03% · MBI: -42.8%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PMI Revenue MBI Revenue PMI Op. Margin MBI Op. Margin Margin Leader
FY2018 N/A $160M N/A -182.7% MBI
FY2019 N/A $280M N/A -128.2% MBI
FY2020 N/A $280M N/A -205.0% MBI
FY2021 N/A $190M N/A -235.4% MBI
FY2022 N/A $150M N/A -126.6% MBI
FY2023 N/A $10M N/A 6814.3% MBI
FY2024 $0M $40M -312.3% 1035.7% MBI
FY2025 $0M $80M -268.4% -221.2% MBI

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MBI BREAKDOWN
98d in phase · OBV NEUTRAL
Current IV 46.5%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MBI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MBI Moat Profile Scale & Operating Efficiency Moat
Insurance - Specialty Operator
Competes within the Insurance - Specialty value chain with $228.1M market capitalization and 22.8% operating margin.
OpEx & R&D Reinvestment 65.3% of Rev ($66M)
90D Engineering Disclosures 0 Published

Investor FAQ PMI vs MBI Key Questions & Quantitative Answers

As of Nov 19, 2026, MBIA Inc. (MBI) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas MBI carries 44.0/100 (HOLD) at $4.37 (87.0x Forward P/E, 22.8% operating margin). Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. MBI 44.0/100 HOLD), MBI captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (22.8% vs. -248.1% operating margin) and revenue trajectory (+46.7% vs. +38.6% YoY). Technical & Structure Timing Caution: PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1); meanwhile MBI is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 40.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MBI leads the Growth & Scale pillar: PMI posts +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin), compared with MBI at +46.7% YoY revenue growth and +0.0% YoY earnings growth on $101M TTM revenue (88.1% gross margin, 22.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PMI cumulative revenue shifted N/A while MBI shifted -50.0%. In operating R&D and SG&A reinvestment, PMI deploys N/A (0 90-day corporate R&D disclosures) versus 65.3% of Rev ($66M) (0 disclosures) for MBI.

MBI screens cheaper on headline valuation multiples. PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin), whereas MBI trades at 87.0x Forward P/E, 87.0x Trailing P/E, 1.71x PEG, and 2.3x EV/Revenue (-118.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PMI (0.0% ROE) versus MBI (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk). By comparison, MBI carries 46.5% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.25β · 31% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.